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Abstract : 
Pro-inflammatory cytokines are important mediators of β-cell demise in type 1 diabetes and similar 
mechanisms are increasingly implicated in type 2 diabetes, where a state of chronic inflammation may 
persist. It is likely that the actions of anti-inflammatory cytokines are also altered in diabetes. 
Cytokines are released from immune cells which may be recruited to the islets in diabetes but they can 
also be produced by islet endocrine cells in response to environmental factors, including enteroviral 
infection. Since enteroviral infection of islet cells may influence the development of diabetes in 
humans we examined the actions of two cytokines, IL-13 and IL-6, whose expression is reported to be 
altered in β-cells during enteroviral infection. Human and rodent islet cells were shown to express 
receptors for both IL-13 and IL-6 and treatment with either cytokine resulted in the rapid 
phosphorylation of STAT3 and STAT6. However, while β-cells were protected against a range of 
cytotoxic insults during exposure to IL-13, treatment with IL-6 enhanced cytotoxicity and Western 
blotting revealed that IL-13 induced one specific isoform of phospho-STAT6 preferentially. Upon 
incubation with both cytokines together, the isoform of STAT6 that was upregulated by IL-13 alone 
was again induced, and the effects of IL-6 on β-cell viability were attenuated. Overall, the results 
suggest that induction of specific isoforms of STAT family transcription factors may underlie the 
cytoprotective actions of IL-13 and they imply that selective targeting of specific STAT-mediated 
signalling components could provide a means to ameliorate the loss of β-cell viability in diabetes.  
Introduction 
Increasing evidence implies that alterations in the balance between anti- and pro-inflammatory 
cytokines may play a role in the development of both type 1 and type 2 diabetes in humans. In type 1 
diabetes, pro-inflammatory cytokines are secreted from CD4
+
 and CD8
+
 lymphocytes and from 
macrophages during the process of insulitis 
1, 2
 whereas the secretion of anti-inflammatory cytokines 
(e.g. IL-4, IL-10 and IL-13) is reduced 
3, 4
. As such, the potentially beneficial effects of these 
molecules on β-cell viability is minimised 5-7. Type 2 diabetes is associated with a chronic low-grade 
islet inflammation and, although the numbers of infiltrating immune cells are reduced by comparison 
with type 1 diabetes, the islet cells may still be exposed to elevated levels of inflammatory mediators 
such as IL-6, TNFα and IL-1β 8, 9. Thus, in both diseases, islet cells encounter a complex 
inflammatory milieu, the exact composition of which will be critical in determining the fate of the β-
cells. Additionally, it is known that islet endocrine cells are, themselves, capable of producing certain 
cytokines (both pro- and anti-inflammatory molecules) 
10, 11
 and it seems probable that agents or 
conditions which alter the profile of islet cell cytokine production may influence their viability. In 
particular, it has been shown that this profile is changed during persistent enteroviral infection of islet 
cells 
12
 and this is of significance because histological evidence implies that human islet cells can 
sustain a persistent enteroviral infection in patients with diabetes 
13, 14
. On this basis, it seems possible 
that the presence of enterovirus could influence the sensitivity of the β-cells to cytotoxic stimuli.  
Cytokines exert their actions via specific cell surface receptors which, when activated, promote 
signalling cascades that culminate in altered gene expression via transcription factors such as NFκB or 
the signal transducer and activator of transcription (STAT) family. The role of NFκB in cytokine 
mediated β-cell toxicity is increasingly well established 2 but the influence of STAT family members 
on β-cell viability has received less attention. Currently, seven members of this family are recognised 
and many cytokines are capable of inducing the activation of more than one isoform 
15, 16
. STAT1 and 
STAT2 have been considered as key targets for activation by pro-inflammatory cytokines whereas 
STAT6 is more frequently stimulated by anti-inflammatory cytokines, including IL-4 and IL-13 
15, 17, 
18
. STAT3 phosphorylation is also sometimes associated with anti-inflammatory activity, but STAT3 
is activated by a range of stimuli, including IL-6 
19
, leptin 
20
 and prolactin 
21
, not all of which are 
associated with anti-inflammatory responses. Therefore, a first aim in the current study, was to 
evaluate the impact of IL-6 and IL-13 on STAT signalling in the pancreatic β-cell.  
IL-13 is known to mediate its effects by  interaction with its cognate cell surface receptor (comprising 
the IL-4 receptor alpha (IL-4Rα) chain and the IL-13 receptor alpha 1 (IL-13Rα1) chain) (reviewed in 
22, 23
) whereas IL-6 binds to a different receptor comprising a unique protein binding subunit (IL-6R), 
which recruits two glycoprotein 130 (GP130) monomers to mediate signal transduction (reviewed in 
24
). Upon interaction of these cytokines with their relevant receptors, Janus kinases (Jak) become 
associated with the cytoplasmic tail of each complex and are phosphorylated at defined sites. 
Activation of the Jak kinases then induces the phosphorylation of key tyrosine residues on the 
cytoplasmic tail of either IL-4Rα or GP130, leading to recruitment and phosphorylation of STAT 
proteins, which then dissociate from the receptor complex, homodimerize and translocate to the 
nucleus to regulate the expression of target genes 
25
. Furthermore, other signalling pathways can be 
induced by IL-6 and IL-13, including the activation of PI-3 kinase and phosphorylation of Akt 
26, 27
. 
Therefore, a further aim was to establish the impact of IL-13 and IL-6 on β-cell viability and to assess 
which signal transduction cascades are important for mediating these effects. A rodent β-cell line 
(INS-1E) was employed as a model system for the study, with key data further validated using a 
newly established human insulin-secreting cell line and/or human islets. 
Results 
Expression of IL-13 and IL-6 receptor components 
Expression of components of the IL-13 receptor was examined by RT-PCR in RNA extracted from 
INS-1E cells or isolated human islets. An appropriately sized amplicon was generated for both 
receptor subunits from each source (Supplemental Fig. 1) and their identities confirmed by direct 
sequencing.  
Expression of IL-6 receptor components was also observed in INS-1E cells (Supplemental Fig. 2A,B) 
or human islets (Supplemental Fig. 2C). It is known that both membrane bound and soluble forms of 
IL-6R (sIL-6R) exist; the latter being generated by alternative splicing of the transcript to yield a 
molecule which lacks the C-terminal transmembrane domain encoded within exon 10 
28
. Therefore, 
primers were designed to amplify a region around exon 10 and RT-PCR analysis revealed that human 
islets express both forms of the IL-6 receptor (Fig.  1).  
IL-13 is cytoprotective in INS-1E cells 
IL-13 is cytoprotective to islet cells treated with pro-inflammatory cytokines 
7
 but, there are few data 
indicating whether IL-13 also influences cell viability in response to other cytotoxic insults. 
Therefore, INS-1E cells were cultured for 96h under serum-deprived conditions as a means to reduce 
viability. Incubation of serum-deprived cells with IL-13 (or a related cytokine, IL-4) significantly 
improved their viability compared to that of untreated controls (Fig. 2A) but co-incubation with both 
IL-13 and IL-4 did not enhance cell viability further (Fig. 2A). The effects of IL-13 (0-20ng/ml) were 
dose-dependent, with an EC50 of ~2ng/ml (Fig. 2B) and it also significantly improved the viability of 
cells treated with the saturated fatty acid, palmitate (250µM) (Fig. 2C).  
Activation of the PI-3K/Akt pathway is unlikely to be responsible for the cytoprotective effect of IL-13 
in INS-1E cells 
Upon the binding of IL-13 to its receptor a number of Jak kinases have been reported to be 
phosphorylated 
29
, and among these, Jak2 is frequently a major substrate. Therefore in the current 
study Jak2 phosphorylation was monitored. Western blotting analysis revealed a basal level of Jak2 
phosphorylation in untreated INS-1E cells and, as expected, this was increased significantly during 
exposure to IL-13 (Fig. 3A,B). 
Subsequent to Jak phosphorylation, IL-13 can induce the phosphorylation of Akt, and in some cell 
types the PI-3K/Akt pathway may contribute to cytoprotection 
26
. To establish whether this pathway 
plays a role in the cytoprotective response induced by IL-13 in INS-1E cells, the PI-3K inhibitor 
wortmannin was employed. As expected, IL-13 improved the viability of serum deprived cells but 
treatment with wortmannin did not influence this cytoprotective response (Fig. 3C). 
The protective effects of IL-13 involve JAK/STAT signalling in INS-1E cells 
In some cell types it has been reported that both STAT6 and STAT3 can become phosphorylated in 
response to IL-13 
15
, and we examined whether this happens in INS-1E (Fig. 4A, 4E) cells and human 
islets (Fig. 4B). Following treatment with IL-13, Western blotting with selective antisera for pSTAT6 
detected an intensely stained band migrating at a molecular weight ~105kDa, corresponding with the 
expected size of STAT6. Surprisingly, however, the antibody also labelled two additional bands 
running at apparently higher molecular weights in INS-1E cells under these conditions (Fig. 4A). A 
similar pattern was also detected in response to IL-4 or after treatment of either a different rodent β-
cell line (BRIN-BD11) or the recently developed human insulin secreting cell line, 1.1B4 with IL-13 
(not shown). Importantly, pre-incubation of the pSTAT6 antiserum with a specific blocking peptide 
corresponding to the epitope employed for antibody generation, abolished the appearance of all three 
bands, thereby confirming the specificity to the antibody (not shown).  
In addition to enhanced phosphorylation of STAT6, an increase in the phosphorylation of STAT3 was 
also detected upon IL-13 stimulation of INS-1E cells (Fig. 4C, 4F) or human islets (Fig. 4D), although 
in these cases, only a single phosphorylated protein was detected. More detailed examination of the 
time-course of STAT6 and STAT3 phosphorylation revealed a temporally similar pattern (Fig. 4G). 
Phosphorylation of each protein occurred within 30 min of stimulation before then declining over the 
remainder of the time-course. Additional experiments revealed, however, that INS-1E cells 
transfected with a STAT3-specific reporter construct exhibited only a modest increase in luciferase 
activity when treated with IL-13 (2.7±1.4 fold change from control) despite the clear increase in 
STAT3 phosphorylation seen under these conditions. To confirm that the phosphorylation of STAT 
proteins occurred via Jak activation, P6, a high affinity competitive global inhibitor of Jak kinases 
30
 
was used. Cells were preincubated with 50-100nM P6 for 2h prior to the addition of IL-13 for a 
further 30min and this effectively antagonised IL-13 induced phosphorylation of STAT6 and STAT3 
(Fig. 5A). The same inhibitor was then employed to determine whether the Jak/STAT pathway could 
be implicated in the cytoprotection mediated by IL-13. The viability of serum starved INS-1E cells 
treated with P6 (100µM) alone was unchanged from that of untreated cells (Fig. 5B). However, when 
cells were exposed to IL-13 in the presence of P6, the inhibitor abrogated the cytoprotective response 
(Fig. 5B). To further support these data, a selective inhibitor of Jak2 activation 
(hexabromocyclohexane) was also employed. This agent exerted little direct effect on the viability of 
serum starved INS-1E cells, however it significantly antagonised the improvement in cell viability 
seen upon IL-13 treatment (Fig. 5C).  
IL-6 enhances STAT phosphorylation, but reduces INS-1E cell viability  
For comparative purposes, the influence of IL-6 on cell viability was then investigated by incubation 
of INS-1E cells under serum deprived conditions for 96h. By contrast with the response seen during 
treatment with IL-13, exposure to IL-6 significantly worsened the viability of the cells under these 
conditions (Fig. 6A). However, IL-6 did not directly influence the viability of INS-1E cells cultured in 
serum-replete medium (Fig. 6B). Treatment of INS-1E cells for 48h with a pro-inflammatory cytokine 
mix (containing TNFα, IFNγ and IL-1β) significantly reduced the viability of β-cells, and exposure to 
IL-6 again potentiated the loss of viability seen under these conditions (Fig. 6B). Additionally, the 
cytotoxic effect of a single cytokine, IL-1β, was also enhanced by IL-6 treatment (Fig. 6C). Since IL-
1β may exert its effects via the induction of iNOS and subsequent production of nitric oxide (NO) we 
examined whether IL-6 influenced NO synthesis. IL-6 alone did not alter nitrite levels (an index of 
NO production) above the control value, whereas IL-1β dramatically increased nitrite production from 
INS-1E cells (Fig. 6D). However, when IL-6 and IL-1β were present in combination, nitrite levels 
were potentiated above that seen with IL-1β alone (Fig. 6D). Similarly, in 1.1B4 cells IL-6 potentiated 
IL-β induced cytotoxicity (Supplemental Fig. 3B) and nitrite production (Supplemental Fig. 3C). 
Finally, IL-6 also significantly potentiated the cytotoxic effects of palmitate treatment in INS-1E cells 
(Fig. 6E). 
IL-6 has been reported to induce STAT3 phosphorylation in human and mouse islets 
19
, however the 
role of STAT6 in IL-6-induced responses has not been investigated. Therefore we assessed the profile 
of STAT activation following treatment of INS-1E with IL-6. As anticipated, STAT3 was rapidly 
phosphorylated in response to the cytokine (Fig. 7A). This response peaked within 15min, and levels 
of the phosphorylated protein remained elevated over the 4h time-course (Fig. 7B). IL-6 treatment 
also dramatically enhanced STAT3-responsive luciferase activity following transfection of INS-1E 
cells with a reporter construct (IL-6: 59.9±24.6 fold increase from control, p<0.05; n=4).  Unlike the 
situation seen with IL-13, however, probing of the protein extract with a pSTAT6 antiserum revealed 
a single immunopositive band upon IL-6 treatment (Fig. 7A). The time-course followed a similar 
pattern to that seen with pSTAT3. Incubation of cells with both IL-6 and IL-13 together, followed by 
Western blotting of the protein extracts with the pSTAT6 antiserum, resulted in an identical pattern of 
bands  compared to that seen with IL-13 alone. Similar data were generated with 1.1B4 cells 
(Supplemental Fig. 3A). Intriguingly, the pSTAT6 band induced by IL-6 migrated in parallel with the 
uppermost band regulated by IL-13 (Fig. 7C). Treatment of human islets with IL-6 revealed a 
different pattern of STAT phosphorylation such that a rapid increase in STAT3 phosphorylation was 
seen but STAT6 phosphorylation was unchanged from control (Fig. 7D). 
The potentiating effects of IL-6 on viability and nitrite synthesis are reduced by incubation of cells 
with IL-13 
Finally, we explored whether IL-13 (or IL-4) can improve the viability of INS-1E cells under 
conditions under when they were also exposed to the usually cytotoxic combination of IL-1β and IL-
6. As expected, IL-1β and IL-6 caused a net loss of cell viability but pre-incubation of the cells with 
IL-13 (or IL-4) for 48 h attenuated this response (Fig. 8A). Culture with either of these anti-
inflammatory cytokines also reduced the nitrite concentration achieved in response to the combination 
of IL-1β and IL-6 (Fig. 8B).  
The phosphorylated forms of STAT6 that were generated within the cells under these conditions were 
also investigated. As described previously, incubation of cells with IL-13 resulted in the induction of 
three bands that were labelled by the pSTAT6 antisera, whereas treatment with IL-6 yielded only a 
single band. When both cytokines were added together (either simultaneously or following a 48h pre-
incubation with IL-13) the pattern of bands detected was identical to that seen during IL-13 treatment 
alone (not shown). 
Discussion 
Pro-inflammatory cytokines are well established as important mediators of β-cell loss during the 
pathogenesis of type 1 diabetes. However, such molecules may also be important in the progression of 
type 2 diabetes as this condition is increasingly recognised as being characterised by a chronic, low 
grade, inflammation within pancreatic islets 
31
. On this basis, it seems likely that the progression of 
both forms of diabetes is influenced by pro-inflammatory mediators operating at the islet level and, by 
extension, this implies that they might be similarly regulated by the presence (or absence) of anti-
inflammatory cytokines within the islet milieu. In support of this, an anti-inflammatory cytokine mix 
was shown to significantly improve the viability of human islets exposed to a cocktail of pro-
inflammatory cytokines in culture 
5
. Furthermore, in the NOD mouse, treatment with anti-
inflammatory cytokines reduced and delayed the onset of spontaneous diabetes 
32-34
 while gene 
transfer of IL-4 into the β-cells of these animals both prevented the onset of diabetes and reversed 
disease progression 
35, 36
. Some cytokines (such as IL-6) have been reported to exert either pro- or 
anti-inflammatory functions depending on the precise conditions 
37
, suggesting that there may be a 
plasticity of response which determines the final outcome at the cellular level.  
Against this background, we have investigated the signalling pathways utilised in β-cells by IL-13 and 
IL-6 and we show that cognate receptors for each, are present in rodent and human β-cells and that 
activation of these can promote Jak/STAT signalling. We also report that human islets may express 
two distinct forms of the IL-6 receptor; representing the membrane-bound form and a smaller isoform 
which lacks the transmembrane domain and, as a consequence, may be released from the cell 
28, 38
. 
The latter is not thought to act as a decoy receptor (which is frequently the case for other soluble 
receptors) but rather, at least in other contexts, it promotes IL-6 trans-signalling in neighbouring cells 
that express GP130 
38
. Therefore, within the islet, release of IL-6R from β-cells might lead to the 
induction of IL-6 signalling in infiltrating immune cells (as seen in the airways of patients during 
allergic asthma 
39
) or, alternatively, to enhanced IL-6 signalling in other islet endocrine cell subtypes.  
We also show that binding of IL-6 and IL-13 to their respective receptors leads to opposite effects on 
β-cell viability. In particular, IL-13 protected β-cells against a range of cytotoxic stimuli, whereas IL-
6 accentuated the deleterious effects of these agents. The principal difference appears to correlate with 
an altered pattern of phosphorylation of STAT6 in response to IL-13 and IL-6 suggesting that the 
status of this transcription factor may be a critical determinant of β-cell viability.  
Previously, we have reported that IL-4 protects β-cells from the cytotoxic effects of pro-inflammatory 
cytokines 
6
 and, in the current study, it has been revealed that IL-13, which often shares a common 
down-stream signalling pathway with IL-4, similarly improves the viability of INS-1E cells cultured 
in the presence of pro-inflammatory cytokines. However, we also show that IL-13 provides 
cytoprotection against the loss of viability associated with serum withdrawal (i.e. upon the removal of 
pro-survival factors) and that caused by incubation of cells with the saturated fatty acid palmitate (a 
condition resembling lipotoxicity). Therefore, rather than simply antagonising the detrimental effects 
of pro-inflammatory cytokines, IL-13 appears to induce a more general ‘cytoprotective phenotype’ in 
the β-cell. As such, these considerations imply that IL-13 activates a critical down-stream signalling 
event that sits at, or beyond, the point of convergence of various pro-apoptotic pathways operating 
within the β-cell.  
Mechanistically, the protective effects of IL-13 are expected to be mediated via its cognate cell 
surface receptor and, in support of this, the expression of both subunits of this receptor (IL-13Rα1 and 
IL-4Rα) were detected at the mRNA level in INS-1E cells and in human islets. Experiments using the 
the PI-3K inhibitor wortmannin failed to influence the cytoprotective response, suggesting that cell 
viability is not regulated principally via changes in Akt phosphorylation in INS-1E cells during 
exposure to IL-13. This result differs from conclusions arising during experiments investigating the 
cytoprotective actions of IL-4 in β-cells 17, implying that subtle differences may exist in the signal 
transduction pathways utilised by IL-4 and IL-13 despite the apparent commonalities they share. In 
our studies, no additivity in response was seen when both cytokines were provided to the cells 
together, implying that each can elicit a maximal cytoprotective response independently of the other.  
Among the potential down-stream targets for the IL-13 and IL-4 receptors are members of the STAT 
family of transcription factors, with increases in STAT6 phosphorylation being frequently reported 
during exposure of cells to either IL-13 or IL-4 
17, 25, 40
. However, additional STAT isoforms are also 
phosphorylated in response to these cytokines 
15, 37
, suggesting a complexity of distal signalling 
events.  
In the present work, increased phosphorylation of both STAT6 and STAT3 was observed during 
exposure of rodent β-cells and human islets to IL-13. It seems possible therefore, that either (or both) 
of these transcription factors might contribute to IL-13 induced cytoprotection. However, additional 
studies with IL-6 imply that altered phosphorylation of STAT3 is unlikely to mediate cytoprotection 
in β-cells since application of this cytokine caused a temporally similar increase in STAT3 
phosphorylation to that observed with IL-13 but, unlike the situation with IL-13, this was associated 
with enhanced cytotoxicity. Furthermore, the activity of a STAT3 reporter construct was only 
marginally elevated by IL-13, whereas IL-6 dramatically increased reporter activity.  Taken together, 
these data imply that changes in STAT3 phosphorylation are not directly and necessarily associated 
with alterations in β-cell viability during exposure to cytokines. By contrast, different conclusions 
emerge from consideration of the phosphorylation of STAT6 in response to IL-6 and IL-13. In the 
case of this transcription factor it was again evident that each cytokine could promote 
phosphorylation, but a markedly different pattern of bands was seen. Cells exposed to IL-13 displayed 
a triple banding pattern when immunoblots were probed with anti-phospho-STAT6 whereas only a 
single isoform was induced by IL-6. This implies that the critical cytoprotective actions of IL-13 may 
result from generation of one of the two differentially phosphorylated isoforms of STAT6. 
Quantitatively, the lowest molecular weight (i.e. fastest migrating) isoform of STAT6 appears to be 
more abundant in the cells since this was detected most readily using an antibody that recognises total 
and phosphorylated STAT6. By contrast, the higher molecular weight (more slowly migrating) band 
was detected only weakly by this antibody. Moreover, it was the faster migrating of the two isoforms 
whose phosphorylation was enhanced selectively in response to IL-13 suggesting that this may be 
responsible for mediating cytoprotection.   
Although the precise identity of the three phospho-STAT6 bands has not been defined, it is 
noteworthy that they were also detected in rat BRIN-BD11 cells and in the newly described human 
insulin secreting cell line, 1.1B4, suggesting that they are not restricted to rodent β-cells. However, in 
human islets only two bands were readily detected by anti-STAT6 antiserum; one of which (the more 
rapidly migrating form) was preferentially upregulated in response to IL-13. The antibody used in our 
study detects preferentially the phosphorylation of tyrosine 641 in STAT6 which is essential for 
activation of the transcription factor. Therefore, all of the STAT6 isoforms detected here are likely to 
contain this residue but it seems probable that some must also be subject to additional post-
translational modification to mediate their altered migration characteristics on SDS gels. Whilst 
various STAT6 isoforms have been identified in other studies, these are usually smaller than the full 
length protein (~105 kDa) 
40
, and are unlikely to be represented within the more slowly migrating 
phosphorylated proteins detected here. However, a number of additional post-translational 
modifications of STAT6 have been described, including altered patterns of serine phosphorylation, 
methylation, acetylation and O-linked N-acetylglucosaminylation 
40
. We hypothesize, therefore, that 
the upper bands seen in cells exposed to IL-6 and IL-13 are likely to represent tyrosine 
phosphorylated isoforms displaying such modifications. More importantly for the present work, we 
suggest that the isoform which is likely to mediate cytoprotection is the most rapidly migrating 
isoform of pSTAT6 since this was induced selectively by IL-13 in cell lines and human islets. 
We also report that exposure of β-cells to IL-6 resulted in potentiation of nitrite production (an index 
of NO generation) in response to pro-inflammatory cytokines, whereas IL-13 inhibited this effect. 
Similar observations have been made after IL-6 treatment 
41
 and elevations in NO synthesis caused by 
IL-6 have been attributed previously to STAT3 activation in INS-1 cells 
42
. Furthermore, IL-13 has 
also been shown to inhibit NO production in colonic mucosa 
43
 and macrophages 
44
. Although NO has 
been implicated in the cytotoxicity induced by pro-inflammatory cytokines, it is unlikely to be of 
relevance to the loss of viability induced by palmitate or serum withdrawal. Therefore, we conclude 
that changes in NO generation are unlikely to underlie the cytoprotection afforded by IL-13.  
The observations reported here assume particular significance when considered in the context of 
immunohistochemical evidence that human islet cells can sustain an enteroviral infection in patients 
with diabetes 
13, 14
 and the finding that enteroviral infection leads to up-regulation of islet IL-6 
generation and a reduction in IL-13 
12
. On this basis, it seems probable that, in either type 1 or type 2 
diabetes, there may be an altered inflammatory milieu within the islets generated both by influent 
immune cells and by changing patterns of cytokine secretion by the endocrine cells themselves which 
favours β-cell loss. Since we now identify possible down-stream signalling pathways that selectively 
mediate the maintenance of cell viability, targeting of these mechanisms may offer a means to slow 
the rate of β-cell loss, especially under conditions where enteroviral infections contribute to this 
process.  
Materials and Methods 
Cell culture 
The rat insulinoma cell line, INS-1E 
45
, was cultured in RPMI-1640 medium containing 11mM 
glucose, 10% FCS, 2mM L-glutamine, 100g/ml streptomycin, 100U/ml penicillin and 50M β-
mercaptoethanol. The human insulin secreting cell line, 1.1B4 
46
, was cultured in similar medium but 
without mercaptoethanol. Cells were cultured in 5% CO2 at 37
o
C and 100% humidity, and were sub-
cultured upon reaching 70-80% confluence. 
Isolated human islets were obtained with ethical approval via the Oxford Centre for Islet 
Transplantation and the Worcestershire Clinical Research Unit. Upon arrival, islet preparations were 
visually assessed for purity using dithizone staining 
47
, and then divided into non-adherent culture 
dishes where they were maintained overnight before treatment. 
Cytokines 
IL-6 and IL-13 were purchased from R & D Systems (506-RL-010 and 1945-RL-025 respectively) 
while all other cytokines were obtained from Sigma-Aldrich. Stock solutions were prepared in PBS 
supplemented with 0.1% BSA. 
Fatty acid treatments 
A stock solution of palmitate was prepared in 50% ethanol and solubilized by heating for 10min at 
70
o
C. Palmitate was bound to 10% fatty-acid free BSA (MP Biomedicals, 100152) by incubation at 
37
o
C for 1h and the complex was added to the cells to yield a 1% solution of BSA. Control cells 
received a final concentration of 1% BSA and 0.5% ethanol with no added fatty acid.  
RT-PCR 
Total RNA was extracted from INS-1E cells or human islets with Trizol reagent. cDNA was 
generated by reverse transcription and amplified by PCR in single tube reactions using custom 
designed primers for rat and human IL-13Rα1, IL-4Rα, IL-6R or GP130 (Supplementary Table 1). 
Typically, the PCR consisted of 35 cycles at 95
o
C for 30s, then 30s at an appropriate annealing 
temperature (Supplementary Table 1) and finally 72
o
C for 30s. PCR products were separated on 1% 
agarose gels by electrophoresis and viewed under long-wave UV illumination. Bands were excised, 
purified and their identities confirmed by direct sequencing (Eurofins MWG Operon). 
Cell viability 
INS-1E cells were seeded into 6-well plates at a density of 10
5
 cells/well. In all experiments, cells 
were incubated with appropriate reagents for up to 96h. Reagents were replaced after 48 h to ensure 
their efficacy did not diminish during the incubation period. To measure viability, cells were 
harvested and resuspended in propidium iodide (10µg/ml) before analysis by flow cytometry 
48
. All 
viability experiments were performed at least three separate times (indicated by n=3), with between 3 
and 6 repeats for each condition within any given experiment. 
Western blotting 
INS-1E cells were grown to confluence in 25cm
2
 growth area flasks before cytokine treatment for 
appropriate time periods. Whole cell proteins were extracted after lysis 
49
. The protein concentration 
of samples was equalized prior to the sample being denatured, and then loaded onto pre-cast Tris-HCl 
buffered 12.5% poly-acrylamide gels. Proteins were separated by electrophoresis and then 
electrotransferred onto a polyvinylidene difluoride membrane. Membranes were blocked in a Tris-
buffered saline solution containing 0.05% Tween and 5% dried milk powder, and then probed with 
primary antibody diluted in blocking solution at 4
oC overnight, with the exception of the β-actin 
antibody which was incubated at room temperature (20
o
C) for 2h. The primary antibodies were raised 
against β-actin (1:10000, Sigma, A5441), p-JAK2 (1:500, Cell Signalling, 3776S), STAT3 (1:1000, 
Cell Signalling, 9132S), p-STAT3 (1:500, Cell Signalling, 9131S), STAT6 (1:200, Santa Cruz, sc-
981) and p-STAT6 (1:200, Santa Cruz, sc-1162R). After washing, membranes were probed with 
appropriate alkaline phosphatase (AP)-conjugated secondary antibodies for 1h (1:25000, Sigma, 
A3687). Bands were detected by exposure of the membrane to X-ray film after development using the 
CDP Star detection system (Sigma, C0712). 
Measurement of nitrite production 
Nitrite production was measured by Griess Assay. Briefly, 100µl of supernatant was collected from 
each well of a 6-well plate in triplicate. Samples and sodium nitrite standards were incubated in the 
dark for 10min with 50µl 1% sulphanilamide in 5% orthophosphoric acid, and then for a further 
10min with 50µl 0.1% naphthylenediamine dihydrochloride before their absorbance was measured at 
562nm. Nitrite concentrations were estimated by comparing the absorbance of the unknown samples 
with those of standards. 
STAT3 reporter assay 
INS-1E cells were seeded at a density of 10
5
 cells/well into 24-well plates. 24h later cells were 
transfected with a STAT3-responsive dual firefly/Renilla luciferase reporter construct (Cignal 
reporter, Qiagen, CCS-90028L) using Attractene transfection reagent according to the manufacturer’s 
instructions (Qiagen, 301005). Following a 4h incubation period, cells were treated with cytokines for 
a further 18h and the STAT3 activity established using the dual-luciferase reporter assay system 
(Promega, E1910).    
Statistics 
Results are expressed as mean values ±SEM unless otherwise stated and statistical significance 
between pairs of experimental groups was assessed by Student’s t-test.  
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Figure legends 
FIG. 1. Human islets express both membrane-bound and soluble isoforms of the IL-6R. (A) cDNA 
was generated from human islet RNA and amplified by RT-PCR using primers spanning exon 10 of 
the IL-6R (membrane-bound form (IL-6R): 265 bp; soluble form (sIL-6R): 171 bp). Bands were 
separated by electrophoresis and visualized under long-wave UV illumination. (B) The identity of 
amplicons was confirmed by the direct sequencing of each excised band. The sequence of each 
amplicon is presented, with exon 10 emboldened.  
FIG. 2. IL-13 treatment protects INS-1E cells against a range of cytotoxic stimuli. Cell death was 
induced either by incubation of INS-1E cells under serum-free conditions for 96 h (A,B) or with 250 
µM palmitate for 48h (C). (A) Serum deprived cells were either untreated (control) or incubated with 
IL-13 (20 ng/ml), IL-4 (2 ng/ml) or both cytokines together. (B) Serum deprived cells were treated 
with increasing concentrations of IL-13 (0-20 ng/ml). (C) For fatty acid experiments, cells were 
treated with IL-13(20 ng/ml) prior to incubation with palmitate. In all cases, the viability of cells was 
measured by flow cytometry using PI staining. (A,C) Data represent mean values ± SEM (n=3), *** 
p<0.001, **p<0.01 as indicated. (B) Data are presented as mean values ± SEM from a representative 
experiment (n=6) which was repeated with similar results.   
FIG. 3. The PI-3K/Akt signal transduction pathway is not involved in IL-13 mediated cytoprotection. 
INS-1E cells were either untreated or stimulated with IL-13 (20 ng/ml). Following treatment, total 
protein was extracted, and the protein concentration equalised to 50 µg. The levels of pJak2 and β-
actin were determined by Western blotting. Blots are representative of three separate experiments. (B) 
The intensity of bands was measured by densitometry, with pJak2 expressed relative to β-actin. (B) 
Data are presented as the mean values from three separate experiments, **p<0.01 relative to control. 
(C) INS-1E cells were incubated under serum starved conditions for 96 h alone (control) or in the 
presence of IL-13 (20 ng/ml), wortmannin (500 nM) or IL-13 + wortmannin. After treatment, the 
viability of cells was measured by flow cytometry following PI staining. Data represent mean values 
±SEM (n=3), *** p<0.001 relative to wortmannin alone. 
FIG. 4. STAT6 and STAT3 are phosphorylated in response to IL-13 in both INS-1E cells and human 
islets. (A, C) INS-1E cells were treated with IL-13 (20 ng/ml) over a time-course of 240 min. (B, D) 
Human islets were also exposed to IL-13 (20 ng/ml) for 30 min. After treatment, total protein was 
extracted, and the protein concentration equalised to either (A) 50 µg, (B) 10 µg (C) 100 µg or (D) 30 
µg per well. The expression levels of (A, B) pSTAT6 and total STAT6 or (C, D) pSTAT3 and total 
STAT3 were determined by Western blot. (A) Lower dotted arrow indicates 105 kDa, middle is 
approximately 150 kDa and upper is around 200 kDa. (A-D) Data are representative of at least three 
separate experiments. (E-F) A series of blots comparing untreated (control) INS-1E cells with those 
exposed to IL-13 (20 ng/ml) for 30 min were analysed by densitometry and pSTAT expressed relative 
to total STAT ((E) STAT6, n=7; (F) STAT3, n=6).  (G) Representative blots were also analysed by 
densitometry and pSTAT expressed relative to total STAT over time.  ** p<0.01, * p<0.05 as 
indicated.   
FIG. 5. IL-13 mediates cytoprotection via a Jak/STAT dependent pathway. (A) INS-1E cells were 
pre-incubated with increasing concentrations of P6 (0-100 nM) prior to a 30 min exposure to IL-13 
(20 ng/ml). Protein was extracted, and the concentration of each sample equalised (25 µg)before 
expression of pSTAT6, STAT6, pSTAT3 and STAT3 were determined by Western blotting. Data are 
representative of two separate experiments. (B,C) Cells were grown under serum deprived conditions 
for 96 h and left untreated (serum free) or exposed to either (B) 100 nM P6, 20 ng/ml IL-13 or IL-13 
+ P6 or (C) 1 µM Jak2 inhibitor, 20 ng/ml IL-13 or IL-13 + Jak2 inhibitor. The viability of cells was 
then monitored by flow cytometry after PI staining. Data represent mean values ±SEM (n=3), *** 
p<0.001 relative to IL-13 alone.  
FIG. 6. IL-6 potentiates the cytotoxic effects of pro-inflammatory cytokines, serum deprivation and a 
saturated fatty acid. The viability of INS-1E cells or the formation of nitrite were induced by (A) 96 h 
serum deprivation; (B) incubation with a pro-inflammatory cytokine mix (pro-inf: 20 ng/ml of IL-1β, 
TNFα and IFNγ) for 48 h; (C,D) treatment with  IL-1β (20 ng/ml) for 48 h; or (E) exposure to 
palmitate (250 µM) for 48h. In all cases, cells were also incubated in the absence or presence of IL-6 
(20 ng/ml) as shown. Cell viability was determined by flow cytometry after PI staining while nitrite 
was measured by the Griess assay. Data represent mean values ± SEM (n=3-4), *** p<0.001 as 
indicated. 
FIG. 7. STAT3 and STAT6 become phosphorylated in response to IL-6 treatment. (A,B) INS-1E cells 
were treated with IL-6 (20 ng/ml) over a 4 h time-course or alternatively (C) with IL-6 for 15 min or 
IL-13 (20 ng/ml) for 30 min. (D) Human islets were treated with IL-6 or IL-13 (20 ng/ml) for 30 min. 
After treatment total protein was extracted, and the protein concentration equalised to either (A) 50 
µg, (C) 40 µg or (D) 15 µg per well. Levels of pSTAT3, STAT3, pSTAT6 and STAT6 were 
determined by Western blotting. (A,C,D) Data are representative of at least two separate experiments. 
(B) The intensity of immunoreactive bands was determined by densitometry and the generation of 
pSTAT expressed relative to total STAT for each isoform. 
FIG. 8. Potentiation of cytokine induced cytotoxicity by IL-6 is sensitive to IL-13. INS-1E cells were 
pre-incubated with IL-13 (20 ng/ml) or IL-4 (20 ng/ml) for 48h before exposure to IL-1β (20 ng/ml) 
and IL-6 (20 ng/ml) for a further 48h. Following treatment, cell viability was measured by flow 
cytometry (A) and nitrite synthesis was assessed by the Griess assay (B). Data represent mean values 
± SEM (n=3), **p<0.01, *** p<0.001 as indicated. 
 
